CLA-2-30:OT:RR:NC:N2:238
Ms. Paula Swanson
Sanofi Pasteur Inc.
Discovery Drive
Swiftwater, PA 18370
RE: The tariff classification of Menactra Vaccine from the United Kingdom
Dear Ms. Swanson:
In your letter dated June 23, 2011, you requested a tariff classification ruling.
The subject product, Menactra Vaccine, contains inactivated Neisseria Meningitidis Polysaccharide Diphtheria Toxoid Conjugate Serogroups A, C, Y, W-135. It is indicated for immunization against invasive meningococcal disease.
The applicable subheading for the Menactra Vaccine will be 3002.20.0000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Human blood; … , cultures of micro-organisms (excluding yeasts) and similar products: Vaccines for human medicine.” The rate of duty will be free.
Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177).
A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact the National Import Specialist at (646) 733-3033.
Sincerely,
Robert B. Swierupski
Director
National Commodity Specialist Division